How a Take-Home Eyelid Hygiene Device Dramatically Improved Dry Eye Treatments in Our Clinical Practice
Not all doctors routinely test for dry eye even though it is one of the most common reasons patients cite for visiting their eye doctor. Complicating matters, many people with dry eye have no symptoms.
DED is most prevalent among contact lens wearers, and it is a universal side effect of refractive surgery. Additionally, DED is a natural consequence of aging.
Patients older than 70 are almost guaranteed to have EDE, MGD, or anterior blepharitis. Dry eye not just a consequence of aging
In the past, DED was seen primarily as a problem of aging and the inability to produce enough tears. But new diagnostic techniques have shown that insufficient tear production is only responsible for about 15% of dry eye cases. Eighty- five percent of dry eye arises from meibomian gland disfunction.2 MGD causes a decrease in oil secretions, which reduces tear breakup time and creates evaporative dry eye conditions.
By implementing a combination of diagnostic devices and state-of-the-art treatments, I am able to significantly impact the trajectory and natural progression of dry eye disease patients in my clinic.
EFFICACY OF SELF-ADMINISTRATION OF A PERSONAL MECHANICAL EYELID
DEVICE FOR THE TREATMENT OF DRY EYE DISEASE, BLEPHARITIS, AND
MEIBOMIAN GLAND DISEASE
David Schanzlin MD1, John Olkowski MD2, John Coble OD3, Wendy Gross OD1, Michael Dash OD2
1Gordon-Schanzlin New Vision Institute, San Diego, CA
2EyeSight Hawaii Vision Institute, Honolulu, HI
3Eyecare of Greenville, Greenville, TX
Corresponding Author: firstname.lastname@example.org
Submitted: November 3, 2019. Accepted: December 17, 2019. Published: January 21, 2020.
A prospective study to evaluate the safety and efficacy of a novel mechanical eyelid device (NuLidsTM by
NuSight Medical, LLC, Rancho Santa Fe, CA) used at home for the treatment of dry eye disease (DED),
blepharitis (anterior and posterior) and meibomian gland disease (MGD).
Seventy-four (74) eyes of thirty-seven (37) patients were self-treated with the NuLidsTM device at home.
Inclusion criteria included blepharitis, MGD and/or DED. After an initial training session, each eyelid was
treated for 15 seconds (total of 1 minute per treatment session per day). The following tests were collected
before the first treatment and after the final treatment: OSDI survey, BCVA, Tear Osmolarity Test (Tear Lab),
Tear Break Up Time (TBUT), Meibomian Gland Score (MGS), Meibomian Glands Yielding Liquid Secretions
(MGYLS), Sicca Ocular Staining Score. Satisfaction with treatment survey was taken after treatment.
All measured parameters had a statistically significant improvement. Symptoms improved based on an
average decrease in OSDI score from 54.2 ± 19.5 (mean ± SD) to 26.7 ± 18.4 (P < 0.001). Tear osmolarity improved from 315 ± 15.7 to 306 ± 13.9 (P = 0.002). TBUT was noted to improve from pretreatment of 4.8 ± 1.7 seconds to post-treatment of 7.9 ± 4.1 seconds (P < 0.001). MGS improved from 8.9 ± 5.1 to 7.0 ± 5.9 (P = 0.01). MGYLS improved from 8.7 ± 6.2 to 15.8 ± 6.9 (P = 0.002). Sicca Ocular Staining Score improved from 2.7 ± 2.1 to 1.4 ± 1.5 (P = 0.002). There were no adverse events. No corneal or conjunctival trauma. No patients dropped out of the trial due to discomfort. 91% of participants agreed or strongly agreed that the device was easy and convenient to use. Of those previously using manual lid scrubs, 82% felt the NuLids device was easier and more comfortable to use. 89% described little or no discomfort. 95% were satisfied or very satisfied with the overall treatment. J Dry Eye Ocul Sur Dis 3(1):e1-e5; January 21, 2020. This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License. ©2020 Shanzlin.
NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies
NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies
Once-daily system complements Avenova and leverages salesforce calls on eyecare specialists
NuLids System® for the Treatment of Dry Eye (Photo: Business Wire)
NuLids System® for the Treatment of Dry Eye (Photo: Business Wire)
October 28, 2019 06:50 AM Eastern Daylight Time
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces an exclusive 90-day agreement with NuSight Medical® to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accumulated scurf from eyelashes and eyelids, while stimulating meibomian gland production in dry eye and blepharitis patients. The NuLids System is available through eyecare professionals for home use by the patient.
“We are delighted to be working with NovaBay, which has a salesforce that is dedicated to the treatment of dry eye and has established relationships with eyecare specialists”
“The NuLids System is highly complementary to Avenova and, in fact, we believe that anyone using this product should also be using Avenova to treat both the symptoms and the underlying cause of blepharitis and bacterial dry eye,” said Justin Hall, NovaBay CEO. “We further believe the NuLids System will elevate our sales calls with ophthalmologists and optometrists and make our salespeople more productive. The NuLids System is available through eyecare professionals, which supports our buy-and-sell sales channel for Avenova. We expect to begin selling the NuLids System at the beginning of November in the greater mid-Atlantic region.”
“We are delighted to be working with NovaBay, which has a salesforce that is dedicated to the treatment of dry eye and has established relationships with eyecare specialists,” said Robert Foster, NuSight Medical CEO. This agreement expands upon our existing professional dealer network with a highly credible distribution partner in a large geographic territory that had previously been underserved. This agreement represents an exciting opportunity to serve dry eye sufferers and their eye care professionals, who may be currently unaware of the NuLids System’s exceptional results in ending or substantially reducing that scratchy, gritty, itching, burning and/or sandy feeling in the eye. One-year patient survey data has shown that 96% of patients surveyed after a 30-day trial reported being either ‘satisfied’ or ‘very satisfied’ with NuLids.”
The NuLids System is easy to use and requires just one minute each day to treat both eyes. Clinical results show a significant reduction in the signs and symptoms associated with dry eye, e.g., an improvement in the number of glands secreting important oils, called meibum, of 81%. These oils are necessary for good tear film quality, comfort and health.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
About NuSight Medical®: Comfort in the Blink of an Eye
Teeny Clean, LLC, dba NuSight Medical, is a medical device company focusing on commercializing and developing its NuLids System® for more effective treatment of Dry Eye Disease and its many related conditions. The NuLids System is the unique, patented, mechanical device that is directed by eye care practitioners for the home-based treatment of Dry Eye Disease and Blepharitis. These markets exceed 400 million people globally.
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding potential partnerships, future collaborations, the impact of new products on our business, and generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, improving sales rep productivity and product distribution, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email email@example.com
Chief Executive Officer and General Counsel
LHA Investor Relations
Cataract surgery is very results oriented and with that comes high expectations from patients in terms of outcomes and improvement in vision. Due to this, we tend to place much emphasis on pre-operative
decisions such as the type of IOL to use. However we need to place equal importance on looking at the ocular surface and meibomian glands to detect any possible dry eye disease and address this prior to surgery in
order to avoid inaccurate presurgical lens calculations, sub-optimal lens choices, and compromised outcomes
“I recently started prescribing the NuLids System to my patients and have been impressed with how quickly my patients clinical signs improve, even the most challenging MGD cases. I have seen chronic Demodex patients do a complete 180 in 2-3 weeks – after other treatments have failed. And, because it makes their eyes feel better almost immediately, patient compliance has never been better!”
Michele Shade, OD
NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System® for Treating Dry Eye Disease
June 24, 2019
Issuance of U.S. Patent No. 10,314,763 Bolsters NuSight Medical’s Intellectual Patent Portfolio
RANCHO SANTA FE, CA., June 24, 2019 (GLOBE NEWSWIRE) — NuSight Medical a medical device company focused on the doctor directed, at-home treatment of dry eye disease to address significant unmet needs in ophthalmic and optometric eye care, today announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of Dry Eye Disease.
U.S. Patent No. 10,314,763 covers the use of the NuLids System treatment for the treatment of dry eye/ocular surface disease, blepharitis and related conditions. “The patent protects our entire NuLids system – the device and methods for its use, the disposable soft-tips, and product safety features.” said Robert Foster, CEO of NuSight Medical.
All 29 claims were approved providing key declarations that involve stimulating the Meibomian glands to effectively treat dry eye. The following is excerpted directly from the abstract:
“an improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands.”
“NuLids treats the predominate cause of Dry Eye Disease, Meibomian Gland Dysfunction, at home every day, which is not practical with in-office treatments. NuLids has brought the highly successful dental model to eyecare. Patients visit their dentist for a deep cleaning and other services that must be professionally performed and then maintain and improve their oral health by brushing and flossing daily while at home. NuLids brings that same paradigm to eye care. Doctors continue to provide office-based dry eye services and patients participate in their continued care by using the clinically validated NuLids System from home,” said John Olkowski, MD, cornea specialist and the inventor of NuLids.
“NuLids is flourishing because it addresses multiple problems for doctors and their patients.” added Foster. “Our professional customers and their patients report excellent results. Doctors benefit from happier, better served patients, and new revenue streams. And, patients look, feel, and see better while maintaining or reducing the cost of treating their disease.”
NuSight Medical has additional patent applications pending.
For more information, visit www.NuSightMedical.com or contact James Laux at: jlaux@NuSightMedical.com  368-5437 ext. 702.
Optometry’s Meeting® is the official annual meeting of the American Optometric Association and American Optometric Student Association. It is the only event that brings the optometry community together to shape the future of the profession, connect with colleagues and get the best continuing education in the industry.
The American Society of Cataract and Refractive Surgery empowers Anterior Segment Surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to Education, Advocacy and Philanthropy. NuSight Medical was founded on the premise that the evolving medical economy requires new approaches to providing more effective and more widely available treatments at lower cost to patients. NuSight Medical provides the devices, disposable tips, education, and support required for Dry Eye
NuSight Medical is proud to attend and present at the Vision Source Exchange in Tampa Florida May 2-4, 2019
The NuSight Medical executive team is comprised of an award-winning, fellowship-trained corneal specialist and visionary industry veterans. We sincerely desire to shatter the old paradigm and bring relief to the millions of Dry Eye sufferers worldwide, at a fraction of the cost of traditional treatment plans.
Doctor-directed dry eye therapy builds broad acceptance with doctors and patients –
Dr. Crystal Brimer, founder of the Dry Eye Institute and owner of Focus Eye Care, Wilmington, NC, is the purchaser of the 2,000 [th] NuLids System sold. NuLids, an innovative doctor-directed, home-use therapy in the fight against dry eye, effectively alleviates symptoms by stimulating and rejuvenating the Meibomian Glands back to a healthier state.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190215005070/en/
Dr. Brimer, who has spent a significant portion of her career studying, researching and treating dry eye, believes NuLids is a promising new therapy that has a meaningful impact on how dry eye symptoms are resolved and repaired.
“Treating my patients with NuLids, I found the system to be a safe, easy to use, and an effective addition to in-office procedures like lid debridement and thermal pulsation,” Brimer stated. “Patients just make the simple one-minute treatment part of their daily personal care routine – like brushing their teeth.” She added, “I believe it is important for the doctor to direct the patient’s therapy, and the patient needs to be an active partner in his or her treatment plan. I like that NuLids provides this. Though we have excellent soaps available, NuLids seems to fill our long-time void of not being able to offer advanced mechanical daily gland stimulation at home.”
“This is a milestone for NuLids,” stated Jim Laux, Chief Commercial Officer of NuSight Medical, maker of NuLids. “Selling our 2,000 [th] unit demonstrates the market’s recognition of NuLids as an effective treatment in-between patient office visits and an important part of the patient’s course of treatment for evaporative dry eye.”
NuLids is a different type of therapy for dry eye – it actually treats the underlying cause of eight out of ten dry eye cases, Meibomian Gland Disease. These tiny glands in the upper and lower lids secrete a small amount of oil that coats the tears and forms a barrier against evaporation; without this oil, tears break down quickly and dry eye occurs. NuLids stimulates and rejuvenates the glands back to a healthy state and oil flow is increased, dramatically reducing clinical signs and symptoms of dry eye.
Evaporative Dry eye is a very common disease in the Unites States; it is estimated that 33-48% of Americans aged 18 and over suffer from dry eye. It is the number one medical reason patients visit eye care professionals.
“NuLids’ introduction into the marketplace has been very successful,” said Laux. “The product is well accepted by doctors and patients and positive clinical data continues to accumulate. Doctors have been waiting for an at-home dry eye therapy that actually treats the cause of evaporative dry eye – not just provide a temporary fix.
“We are also proud that we are able to bring a treatment for dry eye to market that provides new revenues for doctors and is cost effective for patients.” Laux explained, “NuLids is a win-win for doctors and their patients. Doctors benefit from happier patients and adding new home-based revenues to their in-office procedures. Patients are replacing manual lid scrubs and often reducing the need for expensive artificial tear drops, gels, and pharmaceuticals.”
NuLids is manufactured in the United States by NuSight Medical. For more information, visit NuSightMedical.com or call (833) 368-5437.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190215005070/en/
SOURCE: NuSight Medical
Chief Commercial Officer
(833) 368-5437 Ext: 702
RANCHO SANTA FE, California – (Business Wire) – NuSight Medical, a emerging ophthalmic care company, has introduced The NuLids
The system . This novel, safe and effective, doctor prescribed, home use
Medical equipment that effectively treats dry eye was introduced at
American Optometric Association meeting in Denver, CO, June 20-24, 2018.
By gently stimulating, shortening and rejuvenating Meibomian glands
For a healthier state, NuLid’s clinical signs of dry eyes and skin improve
“NuLids is a win-win for treating dry eyes” said Rob
Foster President and CEO, NuSight Medical. “Patients benefit
improved tear film stability, comfort and lubrication that is in violation of dryness
eye. Doctors get an important treatment while helping to build their
practice. And because NuLids is sold only through licensed eye care
Practitioners, doctors have control over the therapy while the patients
perform the treatment at home, improve the practice efficiency. ”
“About 86% of patients with dry eyes have compromised Meibomian gland function
resulting in an unstable tear film and subsequent premature
decomposition of the tear, “said John
Olkowski, MD founder and chairman of NuSight Medical. “The oil
produced by Meibomian glands are an effective barrier to tearing
evaporation. With NuLids that helps with the production and flow of meibum
clinical signs and symptoms of dry eyes are significantly reduced. ”
In a new clinical clinic with several centers
study NuLids System showed a 65% improvement in Tear
Breakup Time and an 81% improvement in Meibomian Glands Yielding Liquid
Secretion. The majority of patients reported twice
improvement of their eye problems after just two weeks of daily use.
NuLids can complement in-office procedures performed by the eye
Doctor. Patients like the NuLids system because it is safe, effective,
and easy to use without any known side effects. They also appreciate
that it is cost effective and can reduce the need for expensive OTC
lubricants and / or co-payments for medicines.
NuLids only takes 60
seconds per day to use and patients adapt quickly to the simple
routine. NuLids I and NuLids II clinical trials showed that 95% of
Patients investigated after 30-day sampling were either reported
“Satisfied” or “Very satisfied” with the overall treatment. ”
Dry eye is known to affect more than 33% of Americans. It is a big
Reason for visit to the eye tower. Dry
The eye is caused by a chronic lack of sufficient lubrication and
moisture on the surface of the eye. The effects of dry eye include
irritation, inflammation and even possible scarring on the surface of
eye. Dry eye is a major medical market in the US – $ 4.0 billion and
grows by 12% per year.
NuSight Medical team is pleased to present such a valuable tool in
fight against the dry eye. We look forward to introducing further
Home-made, home-made products that provide real relief to
patients with dry eye disease in the near future.
NuLids will be featured on Booth # 603 at AOA . For more
information visit: www.nuSightMedical.com,
or call 1 833.3NULIDS [1-833-368-5437].